PDCD1 and colorectal carcinoma: Pembrolizumab, a PD-1 inhibitor, has been approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as a first-line treatment for dMMR/MSI metastatic CRC based on the pivotal phase III KEYNOTE-177 trial [57].